Clinical trials: Toll-Like Receptors
Influenza
Systems Investigation of Vaccine Responses in Aging and Frailty
This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).
- Trial name
- NCT05291676
- Testing
- Fluzone, Fluad
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Yale University
Head and Neck Squamous Cell Carcinoma, Breast Cancer
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma
- Trial name
- NCT02643303
- Testing
- Durvalumab, Tremelimumab, Poly-ICLC
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Ludwig Institute for Cancer Research
Breast Cancer, Breast Neoplasms
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
The purpose of this trial is to determine the safety and efficacy of Imiquimod, a Toll-like receptor 7 agonist in breast cancer (for chestwall recurrences or metastases to the skin).
- Trial name
- NCT00899574
- Testing
- Imiquimod
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Dengue Fever
Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.
- Trial name
- NCT00688389
- Testing
- case/control
- Where
- Taiwan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Rheumatoid Arthritis
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis
- Trial name
- NCT03241108
- Testing
- NI-0101
- Where
- 19 sites in Bosnia and Herzegovina, Bulgaria and 5 more
- Volunteers
- 90 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Pulmonary Tuberculosis, Genetic Variants of Host
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis
Infection with Mycobacterium tuberculosis remains at epidemic levels globally. Innate and adaptive immune responses evolve as protective mechanisms against mycobacterial infection in humans.
- Conditions
- Pulmonary Tuberculosis, Genetic Variants of Host, Immune Response of Host
- Trial name
- NCT00772408
- Where
- 2 sites in Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Asthma
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
GSK2245035 belongs to a novel class of agonist drugs targeted at toll like receptors (TLR). T-helper cell 2 (Th2) driven inflammation is a key patho-physiological mechanism in allergic asthma.
- Trial name
- NCT03707678
- Testing
- GSK2245035, FP-DPI, Albuterol/Salbutamol
- Sponsor
- GlaxoSmithKline
Diabetes, Obesity
A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling
The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
- Trial name
- NCT01740817
- Testing
- Intralipid 20%, Saline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- NCT07355218
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 57 sites in United States, Australia and 15 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Follicular Lymphoma
CD180 Overexpression in Follicular Lymphoma
Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD).
- Trial name
- NCT02978898
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hepatitis B, HBV
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules.
- Trial name
- NCT01590641
- Testing
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
Itch
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch
The aim of this research project is to design a new model of human itch by application of Zyclara cream. Further, the aim is to characterize the model and to verify if the mechanism of action of imiquimod follows the…
- Trial name
- NCT03943407
- Testing
- Zyclara 3.75 % Topical Cream, Prudoxin, Histamine
- Where
- Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aalborg University
Glioblastoma, Glioma
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
This is a phase II study to determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid …
- Trial name
- NCT02754362
- Testing
- Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant
- Where
- United States
- Sponsor
- NYU Langone Health
Solid Tumors
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer. This was a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT03301896
- Testing
- LHC165, PDR001
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Alcoholic Hepatitis
Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis
The purpose of this study is to investigate the role of endotoxins and the endotoxin mediated immune activation pathway in patients with alcoholic hepatitis.
- Trial name
- Heliac (NCT00992888)
- Testing
- Prometheus Liver Dialysis system (Fresenius Medical Care)
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Breast Cancer, Metastatic Breast Cancer
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01421017
- Testing
- Radiation, Imiquimod, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Melanoma
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I a dose escalation is performed and the primary objective is the safety of different doses of TLR-dendritic cell (TLR-DC).
- Trial name
- NCT00940004
- Testing
- autologous dendritic cell vaccination
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Ulcerative Colitis
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of…
- Trial name
- CONCLUDE (NCT04985968)
- Testing
- Cobitolimod 250 mg, Cobitolimod 500 mg
- Where
- 203 sites in United States, Australia and 26 more
- Volunteers
- 171 people
- Sponsor
- InDex Pharmaceuticals
Exercise Training
Effect of Aronia Supplementation on the LPS-CD14-TLR2/4 Axis in Football Players
This randomized, double-blind, placebo-controlled trial will investigate the effects of 8-week Aronia melanocarpa supplementation on exercise-induced activation of the LPS-LBP-CD14-TLR2/TLR4 axis in trained male football players.
- Trial name
- ARONIA-TLR (NCT07829523)
- Testing
- Aronia melanocarpa Extract
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hanna Dziewiecka